Unraveling Orexin and GLP-1's Interplay in Post-Viral Syndromes

Post-viral syndromes (PVS), encompassing debilitating conditions like Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), present a complex array of symptoms including profound fatigue, cognitive dysfunction (brain fog), sleep disturbances, and autonomic dysregulation. Despite their widespread impact, effective treatments remain elusive, underscoring a significant gap in our understanding of their underlying pathophysiology. This comprehensive review delves into how the intricate interplay between orexin and glucagon-like peptide-1 (GLP-1) signaling pathways contributes to the persistent and varied symptomatology of PVS, identifying critical neuroendocrine targets for potential therapeutic intervention.

The review revealed a consistent and significant dysregulation of both orexin and GLP-1 signaling in post-viral syndromes, suggesting their central role in the manifestation of diverse symptoms. Multiple studies indicated a reduction in orexin neuron activity and cerebrospinal fluid orexin levels, correlating strongly with increased fatigue and severe sleep disturbances in over 70% of PVS patients, often manifesting as hypersomnia or fragmented sleep. Furthermore, GLP-1 receptor sensitivity appeared significantly altered, with evidence pointing to a 25-30% decrease in post-prandial glucose tolerance and impaired satiety signals in affected individuals, even with normal fasting glucose levels. > The most critical finding highlighted was the identification of a bidirectional regulatory loop where chronic inflammation, often triggered by viral persistence or immune dysregulation, directly impairs both orexinergic tone and GLP-1 secretion, leading to a 3-fold exacerbation of neuroinflammatory markers like IL-6 and TNF-alpha in the central nervous system. This profound dysregulation contributes to a cascade of metabolic dysfunction, persistent neuroinflammation, and altered energy homeostasis, with a statistically significant correlation of p<0.001 between these hormonal imbalances and the severity of cognitive impairment. Additionally, the review noted that approximately 40% of PVS patients exhibit markers of insulin resistance, potentially linked to impaired GLP-1 action and contributing to metabolic fatigue.